Response to: Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: the real challenge?
| Autor: | Vogel A; Hannover Medical School, Hannover, Germany; Toronto General Hospital, Toronto, Canada; Princess Margaret Cancer Centre, Toronto, Canada. Electronic address: vogela@me.com., Zhen H; Incyte Corporation, Wilmington, USA., Veronese ML; Incyte International Biosciences Sàrl, Morges, Switzerland., Abou-Alfa GK; Memorial Sloan Kettering Cancer Center, New York, USA; Weill Medical College at Cornell University, New York, USA; Trinity College Dublin School of Medicine, Dublin, Ireland. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | ESMO open [ESMO Open] 2024 Nov; Vol. 9 (11), pp. 103937. Date of Electronic Publication: 2024 Oct 17. |
| DOI: | 10.1016/j.esmoop.2024.103937 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|